Claim Missing Document
Check
Articles

Found 2 Documents
Search

FUNDIC GLAND POLYPS: A HOLYSTIC REVIEW Baiq Ayu Rahmawati
Jurnal Medika Hutama Vol. 5 No. 02 Januari (2024): Jurnal Medika Hutama
Publisher : Yayasan Pendidikan Medika Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Gastric polyps are subepithelial protrusions commonly encountered during esophagogastroduodenoscopy (EGD). Fundic gland polyps are the most common type of polyps. The diagnosis of fundic gland polyps can be established through Narrow-band imaging (NBI) and forceps biopsy. Further monitoring is not required for fundic gland polyps that do not have malignant potential. This literature review is conducted using online data sources, namely Sciencedirect, Researchgate, and PubMed. In this literature review, the focus will be on discussing the definition, epidemiology, classification, etiology, risk factors, pathophysiology, clinical manifestations, diagnostic confirmation, management, and differential diagnosis of Fundic gland polyps.
Tuberkulosis Multidrug-Resistant (TB-MDR): Diagnosis and Treatment Baiq Ayu Rahmawati; Rina Lestari
Lombok Medical Journal Vol. 3 No. 2 (2024): Lombok Medical Journal Volume 3 Nomor 2
Publisher : Faculty of Medicine, Universitas Mataram

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.29303/lmj.v3i2.3223

Abstract

Multidrug-Resistant Tuberculosis (MDR-TB) is a TB disease that is resistant to rifampicin and isoniazid with or without other first-line Anti-Tuberculosis Drugs (OAT). Accurate MDR-TB diagnosis and treatment methods are very important to minimize the impact of the disease. The aim of this literature review is to increase understanding of MDR-TB, with a focus on discussing methods of diagnosing and treating MDR-TB. Diagnosis in MDR-TB patients can be done using TCM and sensitivity testing using the Line-2 LPA (Line Probe Assay) method or conventional methods. Treatment is in the form of the use of bedaquiline, prothionamide, linezolid, and moxifloxacin regimens for 6 months; all-oral regimen for 9 months; and long-term regimens for MDR-TB patients